Fluticasone furoate/umeclidinium bromide/vilanterol

Fluticasone furoate/umeclidinium bromide/vilanterol
Combination of
Fluticasone furoateCorticosteroid
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesTrelegy Ellipta, Elebrato Ellipta, Temybric Ellipta
Other namesFF/UMEC/VI
AHFS/Drugs.comMonograph
MedlinePlusa618017
License data
Pregnancy
category
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[6][7] The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

In 2022, it was the 144th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[8][9]

  1. ^ "Fluticasone / umeclidinium / vilanterol (Trelegy Ellipta) Use During Pregnancy". Drugs.com. 13 June 2019. Archived from the original on 4 February 2020. Retrieved 4 February 2020.
  2. ^ "Regulatory Decision Summary for Trelegy Ellipta". 23 October 2014. Archived from the original on 5 January 2023. Retrieved 6 July 2024.
  3. ^ Cite error: The named reference Trelegy Ellipta SmPC was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Trelegy Ellipta FDA label was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference Temybric Ellipta EPAR was invoked but never defined (see the help page).
  6. ^ "Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg) Inhalation Powder". U.S. Food and Drug Administration (FDA). 20 February 2018. Archived from the original on 4 February 2020. Retrieved 4 February 2020.
  7. ^ Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. (May 2018). "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD". The New England Journal of Medicine. 378 (18): 1671–1680. doi:10.1056/NEJMoa1713901. PMID 29668352.{{cite journal}}: CS1 maint: overridden setting (link)
  8. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  9. ^ "Fluticasone; Umeclidinium; Vilanterol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.